These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. [Hemorheologic study in myelodysplastic syndrome]. Rohrberg R; Sternitzky R Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(1):75-80. PubMed ID: 2472331 [No Abstract] [Full Text] [Related]
48. Vitamin K2 therapy for a patient with myelodysplastic syndrome. Yaguchi M; Miyazawa K; Otawa M; Ito Y; Kawanishi Y; Toyama K Leukemia; 1999 Jan; 13(1):144-5. PubMed ID: 10049052 [No Abstract] [Full Text] [Related]
49. Sustained haematological response to high-dose oral alfacalcidol in patients with myelodysplastic syndromes. Kelsey SM; Newland AC; Cunningham J; Makin HL; Coldwell RD; Mills MJ; Grant IR Lancet; 1992 Aug; 340(8814):316-7. PubMed ID: 1353239 [No Abstract] [Full Text] [Related]
51. Clarifications to the standard neutrophil response criteria for clinical trials in myelodysplastic syndromes are needed. Steensma DP; Letendre L; Tefferi A Blood; 2001 May; 97(10):3321-2. PubMed ID: 11368066 [No Abstract] [Full Text] [Related]
52. An under-recognized cause of copper deficiency mimicking myelodysplastic syndrome. Stafford MA; Lim MY Ann Hematol; 2019 Apr; 98(4):1021-1023. PubMed ID: 30357463 [No Abstract] [Full Text] [Related]
53. Danazol therapy in myelodysplastic syndromes. Pozzato G; Franzin F; Moretti M; Campanacci L Haematologica; 1992; 77(1):96. PubMed ID: 1398293 [No Abstract] [Full Text] [Related]